Fortunately, they found the compound 14, a dual allosteric small-molecule inhibitor that can block both SMARCA2 and SMARCA4 ATPase activity, thus exhibiting striking effects on SMARCA4-deficient lung-cancer models [169]. This evidence concerns the gene SMARCA4 and lung carcinoma.